Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials
<p style="text-align:justify;"> To improve strategies for the treatment of BRAF-mutant advanced colorectal cancer (aCRC) patients, we examined individual data from patients treated with chemotherapy alone in three randomised trials to identify points on the treatment pathway where o...
المؤلفون الرئيسيون: | Seligmann, JF, Fisher, D, Smith, CG, Richman, SD, Elliott, F, Brown, S, Adams, R, Maughan, T, Quirke, P, Cheadle, J, Seymour, M, Middleton, G |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Oxford University Press
2016
|
مواد مشابهة
-
2530
حسب: Bernadette McKinney
منشور في: (2017-09-01) -
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
حسب: Adams, R, وآخرون
منشور في: (2017) -
BRAF and NRAS locus-specific variants have different outcomes on survival to colorectal cancer
حسب: Summers, MG, وآخرون
منشور في: (2016) -
FOCUS4-D: Results from a randomised, placebo controlled trial (RCT) of AZD8931 (an inhibitor of signalling by HER1, 2, and 3) in patients (pts) with advanced or metastatic colorectal cancer (aCRC) in tumours that are wildtype (wt) for BRAF, PIK3CA, KRAS and NRAS
حسب: Adams, R, وآخرون
منشور في: (2016) -
Targeting mutant BRAF in colorectal cancer
حسب: Carroll David, وآخرون
منشور في: (2013-01-01)